Anixa Biosciences Inc (ANIX) fair value: what the stock is really worth
As of Nov 10, 2026: fair value (intrinsic value) of Anixa Biosciences Inc stock $2.03, price $3.06, that is 33.7% below the price, quality 48 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.
How to read this chart
60‑month range $2.13 – $6.15 · fair‑value band $1.52 – $2.53 · the $3.06 price screens above the $2.03 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.
Follow Anixa Biosciences in your weekly email
Every Wednesday you see whether Anixa Biosciences is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines that are focused on critical unmet needs in oncology.
Show moreShow less
Its therapeutics programs comprising the development of liraltagene autoleucel, a chimeric endocrine receptor-T cell therapy, a novel form of chimeric antigen receptor-T cell (CAR-T) technology that is focused on treating ovarian cancer.
The company also engaged in the development of a vaccine against breast cancer; and the development of a vaccine discovery program to develop additional cancer vaccines to address intractable cancers, including high incidence malignancies in lung, colon, and prostate.
Its vaccine technologies focus on the discovery of additional retired proteins that may be associated with other forms of cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018.
Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.
Stock analysis
Anixa Biosciences Inc (ANIX) currently trades at $3.06, while our estimate is $2.03, 34% below the price, so the stock looks overvalued today.
Show more
Valuation
None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.
Scenario range: $1.52 (bear) to $2.53 (bull), the price of $3.06 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 48/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.
Anixa Biosciences Inc reported revenue of $0 in FY2025 versus $512K in FY2021. Reported net income was −$10.9M in FY2025.
Key figures
Market cap $105M Micro · EPS (TTM) $−0.2900 · Return on equity −73.2% · Return on assets (EBIT) −52.4% (5-year average) · Free cash flow −$7.2M · Net cash $1.0M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 6 out of 100 (low confidence).
What moves the price
The share trades about 41% below its 52-week high and 30% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −34%, ANIX screens richer than that median.
Fair Value
Bear$1.52Fair Value $2.03Bull$2.53
Price $3.06 · Downside -33.7%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.
Quality Score breakdown
Overall quality48/100
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Profitability0
How much profit the company makes from its sales and capital
Quality Growth25
Are margins and returns getting better?
Cashflow55
Do the profits arrive as real cash?
Financial strength82
Debt, balance sheet and risk of trouble
Investment100
Does it invest with discipline instead of growing at any price?
Low Volatility50
How calm the share price moves, does not count
Price momentum29
Price momentum of the last 3 to 12 months, does not count
In the last 6 months, 4 officers or directors bought shares worth $491,372, most recently on Oct 30, 2026. Buying cluster
BuyAmit KumarChief Executive Officer, Director12× since Jun 12, 2026: 75,188 shares, avg. $2.93$220,604Oct 30, 2026
BuyLewis H Titterton jrDirector6× since Jun 16, 2026: 84,669 shares, avg. $2.85$241,348Oct 23, 2026
BuyMichael CatelaniPresident, COO, & CFO5,500 shares at $2.84$15,620Sep 30, 2026
BuyArnold M BaskiesDirector2× since Jan 28, 2026: 15,000 shares, avg. $2.95$44,200Sep 24, 2026
Plus one other filing such as a grant, option exercise or tax withholding. It is not a market purchase or sale.
Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−100.0%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−28.4%
Revenue growth 38 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−0.9%
’11
’12
’13
’14
’15
’16
’17
’18
’19
’21
’22
’23
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−1,232.0% (2018) → −5,243.3% (2023)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 849 stocks
Beats the industry median on 3/6 measures
A mixed picture versus its industry peers.
Valuation
Quality Score48 · Above median
Fair Value upside−33.7% · Below median
Profitability
Return on assets−68.0% · Bottom 25%
Operating margin (12 months)0.0% · Above median
Growth and dividend
Revenue growth (quarter YoY)0.0% · Above median
Valuation Multiplesvs Biotechnology median · lower = cheaper
P/B6.90× · Priciest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)0· sector 0
PAST (return on equity)0· sector 0
HEALTH (low debt)100· sector 96
DIVIDEND (yield)0· sector 20
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Anixa Biosciences Inc (ANIX) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is $2.03 versus a price of $3.06, about 34% lower (overvalued).
What is the fair value of ANIX?
Our estimate for Anixa Biosciences Inc is $2.03 (as of Nov 10, 2026), built from audited fundamentals. The current price: $3.06.
What is the quality score of ANIX?
Anixa Biosciences Inc has a Quality Score of 48/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Anixa Biosciences Inc (ANIX)?
Our calculated price target is the estimate of $2.03 (as of Nov 10, 2026). Cautious scenario $1.52, optimistic scenario $2.53. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Anixa Biosciences Inc stock forecast for 2026?
Our estimate puts fair value at $2.03, about 34% lower versus a price of $3.06 (overvalued). Cautious scenario $1.52, optimistic scenario $2.53. The calculation is refreshed regularly with new filings.
What is the intrinsic value of Anixa Biosciences Inc (ANIX)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Anixa Biosciences Inc it is $2.03 per share (as of Nov 10, 2026), against a price of $3.06.
Is Anixa Biosciences Inc stock overvalued or undervalued in 2026?
As of Nov 10, 2026, ANIX trades above its calculated fair value: price $3.06, fair value $2.03, a gap of about −34% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ANIX?
No. The price is what the market pays today ($3.06); the fair value is what the company's own numbers justify ($2.03). For Anixa Biosciences Inc the two are $1.03 per share apart. That gap is exactly why we show both numbers side by side.
How much is Anixa Biosciences Inc worth?
The market values Anixa Biosciences Inc at about $105M (market capitalisation, as of Nov 10, 2026). Per share that is $3.06; our models calculate a fair value of $2.03 per share.
What do the bullish and bearish scenarios say about ANIX?
Our models span a range for Anixa Biosciences Inc: cautious scenario $1.52, base $2.03, optimistic $2.53 per share (as of Nov 10, 2026, price $3.06). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Anixa Biosciences Inc (ANIX)?
Balance-sheet figures for Anixa Biosciences Inc (as of Nov 10, 2026): return on equity −73.2%. They feed the Quality Score of 48/100, which measures business quality independently of the share price.
How far is ANIX from its 52-week high?
Anixa Biosciences Inc trades at $3.06, about 41% below its 52-week high of $5.22 and 30% above the low of $2.35 (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of $2.03 is for.
Which stocks are comparable to Anixa Biosciences Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Anixa Biosciences Inc stock attractive at the current price?
The data as of Nov 10, 2026: price $3.06, calculated fair value $2.03 (−34%), Quality Score 48/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. Anixa Biosciences Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Anixa Biosciences Inc (ANIX)?
The closing price on Nov 10, 2026 was $3.06. Our estimate is $2.03, about 34% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Anixa Biosciences Inc right now?
The price sits above even our optimistic bull case ($2.53). The favourable scenario is already priced in. Weak quality (48/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
Key figures of Anixa Biosciences Inc
How large is the market capitalisation of Anixa Biosciences Inc (ANIX)?
The market capitalisation of Anixa Biosciences Inc is $105M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Anixa Biosciences Inc (ANIX)?
Earnings per share at Anixa Biosciences Inc are $−0.2900. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Anixa Biosciences Inc (ANIX)?
The return on equity (ROE) of Anixa Biosciences Inc is −73.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Anixa Biosciences Inc (ANIX)?
On an EBIT basis the return on assets of Anixa Biosciences Inc is −52.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How much free cash flow does Anixa Biosciences Inc (ANIX) generate?
The free cash flow of Anixa Biosciences Inc is −$7.2M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Anixa Biosciences Inc (ANIX) hold?
Anixa Biosciences Inc holds more cash than debt, $1.0M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Anixa Biosciences Inc in the live analysis
One click puts Anixa Biosciences Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 10, 2026
